Among these, GLS emerged as a key gene, showing low methylation levels and high mRNA expression, which were associated with poor prognosis, significant alterations in the tumor immune microenvironment, and differential sensitivity to ICIs and chemotherapeutic agents. This evidence concerns the gene GLS and neoplasm.